Unique Case of Vitiligo Development During Nivolumab Treatment

Introduction to Nivolumab and Its Mechanism

A recent report has highlighted an intriguing case of a patient with melanoma who developed vitiligo spots while undergoing treatment with nivolumab. Nivolumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1). This protein is found on various immune cells, including CD4+ and CD8+ T cells, B cells, monocytes, natural killer cells, and dendritic cells. PD-1 plays a crucial role in maintaining immune tolerance, as evidenced by studies showing that mice lacking PD-1 can develop several autoimmune diseases.

Tumor cells frequently overexpress PD-1 ligands, which interact with PD-1 on activated T-cells, leading to suppressed immune responses against tumors. Nivolumab’s action involves blocking this interaction, thus enabling activated T-cells to effectively attack and eliminate cancer cells. The U.S. Food and Drug Administration has approved nivolumab for treating melanoma that is either unresectable or metastatic. Additionally, it is indicated for various other cancers, including classical Hodgkin lymphoma and non-small cell lung cancer.

Patient Case Overview

A recent publication in JAMA Dermatology discusses a patient who developed melanoma on his right knee in his 30s. Following surgical removal of the tumor and the right ilioinguinal lymph node, the cancer recurred multiple times over the next eight months. A CAT scan conducted four years post-surgery revealed metastasis to the right pelvis and lower thigh. Subsequently, the patient began a three-month course of nivolumab treatment.

During this therapy, the patient experienced a complete resolution of the pelvic metastasis and other secondary tumor sites. However, he also developed vitiligo spots on his chest, the backs of his hands, and his back. Eight months after discontinuing nivolumab, the vitiligo spots faded, while CAT scans revealed new brain metastases. Surgical intervention was performed to remove tumor tissue from the brain, followed by radiation therapy. Unfortunately, despite these efforts, additional lesions emerged in the brain and liver.

Continued Therapy and Observations

The patient then underwent another four cycles of therapy, but there was no increase in existing vitiligo spots or the emergence of new ones. Nevertheless, tumor progression continued despite ongoing nivolumab treatment. The authors of the report suggest that this case could represent the first documented instance of vitiligo repigmentation following nivolumab therapy.

They propose that nivolumab activates cytotoxic T cells, prompting them to attack both melanoma cells and normal melanocytes due to the shared antigens between the two. This immune response may lead to both tumor reduction and the depigmentation characteristic of vitiligo. Upon withdrawal of nivolumab, a decrease in melanocytic antibodies and T-cells in the epidermis may result in repigmentation, which coincided with tumor relapse in this case.

Conclusion and Implications

This significant study is the first to establish a potential link between vitiligo repigmentation and tumor relapse following nivolumab treatment. Previously, there have been no recorded instances of vitiligo disappearing after nivolumab or other anti-PD-1 therapies. This unique case suggests that repigmentation could serve as an indicator of tumor re-emergence either during or after therapy.

References

1. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17-37. doi:10.1007/82_2010_116
2. Nivolumab. National Cancer Institute. Updated April 5, 2023. https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab
3. Nakamura Y, Teramoto Y, Asami Y, et al. Nivolumab therapy for treatment-related vitiligo in a patient with relapsed metastatic melanoma. JAMA Dermatol. 2017;153(9):942-944. doi:10.1001/jamadermatol.2017.1679